UNSPSC 51171652: Prucalopride hydrochloride

This classification denotes a serotonin agonist C18H26ClN3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M8IYX9Z79V, chemically known as 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide hydrochloride, but more generally known as prucalopride hydrochloride, which bears US NIH Compound Identifier 9931054. Most nations, for tariff and trade purposes, schedule prucalopride hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, PRUCALOPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COCCCN1CCC(CC1)NC(=O)C2CC(C(C3C2OCC3)N)CL.CL.

UNSPSC 51171652 Prucalopride hydrochloride (Commodity) does not align with the recent state and local procurement activity tagged to it. The source contains one recent opportunity—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—which solicits laboratory testing infrastructure, staffing, and specimen handling rather than a pharmaceutical product. The RFP calls for immunoassay screening with LC/MS/MS or GC/MS confirmation, operation of an Interactive Voice Response system for randomized testing notifications, collection-site staffing at two locations in the Dallas-Fort Worth area, and alternative testing methodologies (oral fluid and hair), with no pharmaceutical procurement component present.

Collin County, Texas, is the sole issuing body represented in the recent opportunity block. The county's RFP 2026-327 carries an estimated contract value of $600,000 over two years commencing September 1, 2026, with three optional one-year renewal periods, and an anticipated award date of August 10, 2026. Pricing is structured on a per-test basis for approximately 25,031 annual tests across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with all costs including freight, delivery, insurance, and staffing embedded in per-test pricing and no additional surcharges permitted. The code shows negligible relevant recent activity for the pharmaceutical product it nominally describes.